Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Real-time Estimate Cboe BZX  -  08:44 2022-12-07 am EST
175.55 USD   -0.32%
04:38aGSK, Pfizer, Sanofi Breathe Sigh Of Relief After US Court Tosses Lawsuits On Zantac Cancer Link
MT
12/06Major Pharma Companies to Remain Defensive Through at least H1 2023 Amid M&As, New Products Focus, Morgan Stanley Says
MT
12/06Morgan Stanley Trims Price Target on Johnson & Johnson to $176 From $178, Maintains Equalweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company

09/28/2022 | 07:45am EST

Johnson & Johnson took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company. The new corporate brand comes to life through a compelling purpose, and a timeless visual brand. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and vue, referencing sight.

With rich knowledge of human needs and deep consumer insights, Kenvue will deliver meaningful, personal health solutions. Kenvue's purpose, Realize the Extraordinary Power of Everyday Care, will guide the company's actions and long-term aspirations, from strategy to talent philosophy, and more. Along with the name and purpose, Kenvue's visual identity represents the company's timelessness, while allowing space for its iconic brands to also have a home.

The new logo centers on the “K” symbol, embodying the company's strengths – the geometry of the rectangle representing scientific precision and the round edges evoking the warmth of care. The corporate name is depicted in a distinctive logotype in a rich green. This strong, distinctive color works in harmony with the multicolored palette of the company's portfolio of well-known brands.


ę S&P Capital IQ 2022
All news about JOHNSON & JOHNSON
04:38aGSK, Pfizer, Sanofi Breathe Sigh Of Relief After US Court Tosses Lawsuits On Zantac Can..
MT
12/06Major Pharma Companies to Remain Defensive Through at least H1 2023 Amid M&As, New Prod..
MT
12/06Morgan Stanley Trims Price Target on Johnson & Johnson to $176 From $178, Maintains Equ..
MT
12/05Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel ..
PU
12/05Yumanity Therapeutics to Pay Special Cash Dividend Related to Planned Asset Sale, Kinet..
MT
12/05Johnson & Johnson's Janssen Global Services Unit Says No Plans to Bid for Horizon Thera..
MT
12/03Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel ..
PU
12/02Insider Sell: Johnson & Johnson
MT
12/02Sanofi Says Any Potential Offer for Horizon Therapeutics Will Be Made in Cash
MT
12/01Global markets live: General Electric, Tesla, Apple, Salesforce, Boe..
MS
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 035 M - -
Net income 2022 20 677 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 21,6x
Yield 2022 2,47%
Capitalization 460 B 460 B -
EV / Sales 2022 4,73x
EV / Sales 2023 4,51x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 176,10 $
Average target price 181,81 $
Spread / Average Target 3,24%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.51%460 411
ELI LILLY AND COMPANY33.69%350 179
ABBVIE INC.20.92%289 437
NOVO NORDISK A/S21.77%285 921
PFIZER, INC.-14.09%279 038
MERCK & CO., INC.42.13%276 181